Next Article in Journal
Interactions between a Heparin Trisaccharide Library and FGF-1 Analyzed by NMR Methods
Next Article in Special Issue
New Insights in Thyroid Cancer and p53 Family Proteins
Previous Article in Journal
Age-Related Changes in Immunological and Physiological Responses Following Pulmonary Challenge
Previous Article in Special Issue
Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours
 
 
Review

Differentiated Thyroid Cancer—Treatment: State of the Art

Department of Nuclear Medicine, University of Regensburg, 93053 Regensburg, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2017, 18(6), 1292; https://doi.org/10.3390/ijms18061292
Received: 6 April 2017 / Revised: 5 June 2017 / Accepted: 5 June 2017 / Published: 17 June 2017
(This article belongs to the Special Issue Current Knowledge in Thyroid Cancer—From Bench to Bedside)
Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence has increased over the last few decades. It derives from follicular thyroid cells. Generally speaking, the prognosis is excellent. If treatment according to the current guidelines is given, cases of recurrence or persistence are rare. DTC requires special expertise by the treating physician. In recent years, new therapeutic options for these patients have become available. For this article we performed a systematic literature review with special focus on the guidelines of the American Thyroid Association, the European Association of Nuclear Medicine, and the German Society of Nuclear Medicine. For DTC, surgery and radioiodine therapy followed by levothyroxine substitution remain the established therapeutic procedures. Even metastasized tumors can be cured this way. However, in rare cases of radioiodine-refractory tumors, additional options are to be discussed. These include strict suppression of thyroid-stimulating hormone (also known as thyrotropin, TSH) and external local radiotherapy. Systemic cytostatic chemotherapy does not play a significant role. Recently, multikinase or tyrosine kinase inhibitors have been approved for the treatment of radioiodine-refractory DTC. Although a benefit for overall survival has not been shown yet, these new drugs can slow down tumor progression. However, they are frequently associated with severe side effects and should be reserved for patients with threatening symptoms only. View Full-Text
Keywords: differentiated thyroid cancer; radioiodine therapy; targeted therapy; tyrosine kinase inhibitors differentiated thyroid cancer; radioiodine therapy; targeted therapy; tyrosine kinase inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Schmidbauer, B.; Menhart, K.; Hellwig, D.; Grosse, J. Differentiated Thyroid Cancer—Treatment: State of the Art. Int. J. Mol. Sci. 2017, 18, 1292. https://doi.org/10.3390/ijms18061292

AMA Style

Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated Thyroid Cancer—Treatment: State of the Art. International Journal of Molecular Sciences. 2017; 18(6):1292. https://doi.org/10.3390/ijms18061292

Chicago/Turabian Style

Schmidbauer, Benedikt, Karin Menhart, Dirk Hellwig, and Jirka Grosse. 2017. "Differentiated Thyroid Cancer—Treatment: State of the Art" International Journal of Molecular Sciences 18, no. 6: 1292. https://doi.org/10.3390/ijms18061292

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop